新型高敏肌钙蛋白I检测在疑似急性冠脉综合征中的应用
在1920例疑似急性冠脉综合征患者中评估Siemens Atellica高敏肌钙蛋白I检测的早期排除路径性能。30天心梗或心源性死亡发生率为14.4%。High-STEACS路径排除63%患者,漏诊5例,阴性预测值99.5%;ESC 1小时路径阴性预测值99.0%;ESC 3小时路径排除65%但漏诊25例,阴性预测值98.0%。使用低浓度阈值进行风险分层的路径比依赖99百分位诊断阈值排除心梗的路径漏诊更少。
要点
- High-STEACS路径排除63%患者,阴性预测值99.5%,仅漏诊5例。
- ESC 1小时路径阴性预测值99.0%,性能与High-STEACS相似。
- ESC 3小时路径排除65%患者但漏诊25例,阴性预测值98.0%。
核心结论
- 新型高敏肌钙蛋白I检测可安全识别心梗或心源性死亡低风险患者。
- 使用低浓度阈值进行风险分层的诊断路径比依赖99百分位排除心梗的路径漏诊更少。
研究设计与样本
- 在1920例疑似急性冠脉综合征患者中评估Siemens Atellica高敏肌钙蛋白I检测(99百分位:女性34 ng/L,男性53 ng/L)。
- 评估三种路径:High-STEACS、ESC 1小时路径(低风险分层阈值)和ESC 3小时路径(99百分位诊断阈值)用于排除心梗。
主要发现
- 30天主要终点(心梗或心源性死亡)发生率为14.4%(277/1920)。
- High-STEACS路径排除63%患者(1218/1920),漏诊5例,阴性预测值99.5%(95%CI 99.1%–99.8%)。
- ESC 1小时路径阴性预测值99.0%(95%CI 97.6%–99.8%)。
- ESC 3小时路径排除65%患者(1248/1920),漏诊25例,阴性预测值98.0%(95%CI 97.1%–98.7%)。
关键数值与推荐
- 高敏肌钙蛋白I检测99百分位:女性34 ng/L,男性53 ng/L。
- High-STEACS路径阴性预测值99.5%(95%CI 99.1%–99.8%)。
- ESC 1小时路径阴性预测值99.0%(95%CI 97.6%–99.8%)。
- ESC 3小时路径阴性预测值98.0%(95%CI 97.1%–98.7%)。
临床怎么用
- 可采用High-STEACS或ESC 1小时路径使用低浓度阈值进行早期风险分层以安全排除心梗。
- 依赖99百分位诊断阈值的ESC 3小时路径漏诊事件较多,需谨慎用于排除心梗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-sensitivity cardiac troponin assays enable the early risk stratification of patients with suspected acute coronary syndrome to identify those at low risk of myocardial infarction or cardiac death. We evaluated the performance of a novel high-sensitivity cardiac troponin I assay in early rule out pathways. METHODS: In 1920 patients with suspected acute coronary syndrome, cardiac troponin was measured using the Siemens Atellica high-sensitivity cardiac troponin I assay (99th centile: 34 ng/L women, 53 ng/L men). We evaluated three pathways which use either low risk-stratification thresholds of cardiac troponin (High-SensitivityTroponin in the Evaluation of patients with Acute Coronary Syndrome (High-STEACS) and the European Society of Cardiology (ESC) 1 hour pathway) or the 99th centile diagnostic threshold (ESC 3 hour pathway) to rule out myocardial infarction. RESULTS: The primary outcome of myocardial infarction or cardiac death at 30 days occurred in 14.4% (277/1920). The High-STEACS pathway ruled out 63% of patients (1218/1920), with five missed events for a negative predictive value (NPV) of 99.5% (95% CI (CI) 99.1% to 99.8%). Similar performance was observed for the ESC 1 hour pathway with an NPV of 99.0% (97.6% to 99.8%). In contrast, the ESC 3 hour pathway ruled out 65% of patients (1248/1920), but missed 25 events for an NPV of 98.0% (97.1% to 98.7%). CONCLUSIONS: A novel high-sensitivity cardiac troponin I assay can safely identify patients at low risk of myocardial infarction or cardiac death. Diagnostic pathways that use low cardiac troponin concentrations for risk stratification miss fewer events than those that rely on the 99th centile to rule out myocardial infarction. TRIAL REGISTRATION: NCT1852123.
引用
- Chapman AR, Fujisawa T, Lee KK, et al. Novel high-sensitivity cardiac troponin I assay in patients with suspected acute coronary syndrome. Heart. 2018. PMID: 30442743. doi:10.1136/heartjnl-2018-314093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。